Just ahead of the Thanksgiving holiday, Eli Lilly (NYSE: LLY) announced the third late-stage clinical failure for its Alzheimer’s disease candidate. The stock had given up some ground this year, and following the flop, it’s down about 20% in 2016. Meanwhile, it’s hardly been a banner year for Johnson & Johnson (NYSE: JNJ), but its stock is up about 10.2% this year.
